December 14th 2020
Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.
December 3rd 2020
Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.
November 25th 2020
Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.
November 18th 2020
Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.
November 12th 2020
Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.
June 12th 2020
Joshua Brody, MD, discusses Fas and its impact on bystander killing in patients with non-Hodgkin lymphoma.
May 28th 2020
Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.
April 22nd 2020
Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.
April 16th 2020
Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.
February 28th 2020
Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.
November 24th 2014
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).
November 25th 2013
Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.